Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma

Clinical and prognostic implications

Massimiliano Berretta, Carla Cavaliere, Lara Alessandrini, Brigida Stanzione, Gaetano Facchini, Luca Balestreri, Tiziana Perin, Vincenzo Canzonieri

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

HCC represents the sixth most common cancer worldwide and the second leading cause of cancer-related death. Despite the high incidence, treatment options for advanced HCC remain limited and unsuccessful, resulting in a poor prognosis. Despite the major advances achieved in the diagnostic management of HCC, only one third of the newly diagnosed patients are presently eligible for curative treatments. Advances in technology and an increased understanding of HCC biology have led to the discovery of novel biomarkers. Improving our knowledge about serum and tissutal markers could ultimately lead to an early diagnosis and better and early treatment strategies for this deadly disease. Serum biomarkers are striking potential tools for surveillance and early diagnosis of HCC thanks to the non-invasive, objective, and reproducible assessments they potentially enable. To date, many biomarkers have been proposed in the diagnosis of HCC. Cholangiocarcinoma (CCA) is an aggressive malignancy, characterized by early lymph node involvement and distant metastasis, with 5-year survival rates of 5%-10%. The identification of new biomarkers with diagnostic, prognostic or predictive value is especially important as resection (by surgery or combined with a liver transplant) has shown promising results and novel therapies are emerging. However, the relatively low incidence of CCA, high frequency of co-existing cholestasis or cholangitis (primary sclerosing cholangitis -PSC- above all), and difficulties with obtaining adequate samples, despite advances in sampling techniques and in endoscopic visualization of the bile ducts, have complicated the search for accurate biomarkers. In this review, we attempt to analyze the existing literature on this argument.

Original languageEnglish
Pages (from-to)14192-14220
Number of pages29
JournalOncotarget
Volume8
Issue number8
DOIs
Publication statusPublished - 2017

Fingerprint

Cholangiocarcinoma
Hepatocellular Carcinoma
Biomarkers
Early Diagnosis
Sclerosing Cholangitis
Cholangitis
Second Primary Neoplasms
Cholestasis
Incidence
Therapeutics
Bile Ducts
Neoplasms
Survival Rate
Lymph Nodes
Neoplasm Metastasis
Technology
Transplants
Liver
Serum

Keywords

  • Cholangiocarcinoma
  • Hepatocellular carcinoma
  • Metastasis
  • Prognosis
  • Serum markers
  • Tissue markers

ASJC Scopus subject areas

  • Oncology

Cite this

Berretta, M., Cavaliere, C., Alessandrini, L., Stanzione, B., Facchini, G., Balestreri, L., ... Canzonieri, V. (2017). Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: Clinical and prognostic implications. Oncotarget, 8(8), 14192-14220. https://doi.org/10.18632/oncotarget.13929

Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma : Clinical and prognostic implications. / Berretta, Massimiliano; Cavaliere, Carla; Alessandrini, Lara; Stanzione, Brigida; Facchini, Gaetano; Balestreri, Luca; Perin, Tiziana; Canzonieri, Vincenzo.

In: Oncotarget, Vol. 8, No. 8, 2017, p. 14192-14220.

Research output: Contribution to journalReview article

Berretta, M, Cavaliere, C, Alessandrini, L, Stanzione, B, Facchini, G, Balestreri, L, Perin, T & Canzonieri, V 2017, 'Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: Clinical and prognostic implications', Oncotarget, vol. 8, no. 8, pp. 14192-14220. https://doi.org/10.18632/oncotarget.13929
Berretta, Massimiliano ; Cavaliere, Carla ; Alessandrini, Lara ; Stanzione, Brigida ; Facchini, Gaetano ; Balestreri, Luca ; Perin, Tiziana ; Canzonieri, Vincenzo. / Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma : Clinical and prognostic implications. In: Oncotarget. 2017 ; Vol. 8, No. 8. pp. 14192-14220.
@article{0ee448e46e944abe9ff85b3b68b989e0,
title = "Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: Clinical and prognostic implications",
abstract = "HCC represents the sixth most common cancer worldwide and the second leading cause of cancer-related death. Despite the high incidence, treatment options for advanced HCC remain limited and unsuccessful, resulting in a poor prognosis. Despite the major advances achieved in the diagnostic management of HCC, only one third of the newly diagnosed patients are presently eligible for curative treatments. Advances in technology and an increased understanding of HCC biology have led to the discovery of novel biomarkers. Improving our knowledge about serum and tissutal markers could ultimately lead to an early diagnosis and better and early treatment strategies for this deadly disease. Serum biomarkers are striking potential tools for surveillance and early diagnosis of HCC thanks to the non-invasive, objective, and reproducible assessments they potentially enable. To date, many biomarkers have been proposed in the diagnosis of HCC. Cholangiocarcinoma (CCA) is an aggressive malignancy, characterized by early lymph node involvement and distant metastasis, with 5-year survival rates of 5{\%}-10{\%}. The identification of new biomarkers with diagnostic, prognostic or predictive value is especially important as resection (by surgery or combined with a liver transplant) has shown promising results and novel therapies are emerging. However, the relatively low incidence of CCA, high frequency of co-existing cholestasis or cholangitis (primary sclerosing cholangitis -PSC- above all), and difficulties with obtaining adequate samples, despite advances in sampling techniques and in endoscopic visualization of the bile ducts, have complicated the search for accurate biomarkers. In this review, we attempt to analyze the existing literature on this argument.",
keywords = "Cholangiocarcinoma, Hepatocellular carcinoma, Metastasis, Prognosis, Serum markers, Tissue markers",
author = "Massimiliano Berretta and Carla Cavaliere and Lara Alessandrini and Brigida Stanzione and Gaetano Facchini and Luca Balestreri and Tiziana Perin and Vincenzo Canzonieri",
year = "2017",
doi = "10.18632/oncotarget.13929",
language = "English",
volume = "8",
pages = "14192--14220",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "8",

}

TY - JOUR

T1 - Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma

T2 - Clinical and prognostic implications

AU - Berretta, Massimiliano

AU - Cavaliere, Carla

AU - Alessandrini, Lara

AU - Stanzione, Brigida

AU - Facchini, Gaetano

AU - Balestreri, Luca

AU - Perin, Tiziana

AU - Canzonieri, Vincenzo

PY - 2017

Y1 - 2017

N2 - HCC represents the sixth most common cancer worldwide and the second leading cause of cancer-related death. Despite the high incidence, treatment options for advanced HCC remain limited and unsuccessful, resulting in a poor prognosis. Despite the major advances achieved in the diagnostic management of HCC, only one third of the newly diagnosed patients are presently eligible for curative treatments. Advances in technology and an increased understanding of HCC biology have led to the discovery of novel biomarkers. Improving our knowledge about serum and tissutal markers could ultimately lead to an early diagnosis and better and early treatment strategies for this deadly disease. Serum biomarkers are striking potential tools for surveillance and early diagnosis of HCC thanks to the non-invasive, objective, and reproducible assessments they potentially enable. To date, many biomarkers have been proposed in the diagnosis of HCC. Cholangiocarcinoma (CCA) is an aggressive malignancy, characterized by early lymph node involvement and distant metastasis, with 5-year survival rates of 5%-10%. The identification of new biomarkers with diagnostic, prognostic or predictive value is especially important as resection (by surgery or combined with a liver transplant) has shown promising results and novel therapies are emerging. However, the relatively low incidence of CCA, high frequency of co-existing cholestasis or cholangitis (primary sclerosing cholangitis -PSC- above all), and difficulties with obtaining adequate samples, despite advances in sampling techniques and in endoscopic visualization of the bile ducts, have complicated the search for accurate biomarkers. In this review, we attempt to analyze the existing literature on this argument.

AB - HCC represents the sixth most common cancer worldwide and the second leading cause of cancer-related death. Despite the high incidence, treatment options for advanced HCC remain limited and unsuccessful, resulting in a poor prognosis. Despite the major advances achieved in the diagnostic management of HCC, only one third of the newly diagnosed patients are presently eligible for curative treatments. Advances in technology and an increased understanding of HCC biology have led to the discovery of novel biomarkers. Improving our knowledge about serum and tissutal markers could ultimately lead to an early diagnosis and better and early treatment strategies for this deadly disease. Serum biomarkers are striking potential tools for surveillance and early diagnosis of HCC thanks to the non-invasive, objective, and reproducible assessments they potentially enable. To date, many biomarkers have been proposed in the diagnosis of HCC. Cholangiocarcinoma (CCA) is an aggressive malignancy, characterized by early lymph node involvement and distant metastasis, with 5-year survival rates of 5%-10%. The identification of new biomarkers with diagnostic, prognostic or predictive value is especially important as resection (by surgery or combined with a liver transplant) has shown promising results and novel therapies are emerging. However, the relatively low incidence of CCA, high frequency of co-existing cholestasis or cholangitis (primary sclerosing cholangitis -PSC- above all), and difficulties with obtaining adequate samples, despite advances in sampling techniques and in endoscopic visualization of the bile ducts, have complicated the search for accurate biomarkers. In this review, we attempt to analyze the existing literature on this argument.

KW - Cholangiocarcinoma

KW - Hepatocellular carcinoma

KW - Metastasis

KW - Prognosis

KW - Serum markers

KW - Tissue markers

UR - http://www.scopus.com/inward/record.url?scp=85013392545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013392545&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.13929

DO - 10.18632/oncotarget.13929

M3 - Review article

VL - 8

SP - 14192

EP - 14220

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 8

ER -